Prognostic Value of BNP in MCS - a 25 Year Follow up Study
Recruiting
Observational Study
Heart Failure
Left Ventricular Assist Device
Prognosis
Durable Mechanical Support Device
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Rigshospitalet, Denmark · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
* Age\>18 years
Exclusion Criteria:
* No consent
Contacts